Rachid Rafia MSc

Rachid Rafia

HEDS, ScHARR
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA
UK

Office:

Tel: (+44) (0)114 222 0739
Fax: (+44) (0)114 272 4095

Biography

I joined ScHARR in February 2008, having completed a MSc in management of health care and health economics at the University Paris 1 Pantheon Sorbonne. I have worked as a health economic consultant and worked mainly on infectious diseases. Since joining ScHARR, I have gained experienced in modelling diseases such as Friedreich´s ataxia, multiple sclerosis, soft tissue sarcoma, psoriatic arthritis and different type of cancers. I was also involved in the modelling of the impact of reducing the blood alcohol concentration level in the England and Wales.

I am currently working on modelling breast cancer screening in the elderly.

Research interests

My research interests are:

Health economics and economic evaluation
Health economic modelling for decision making

Teaching interests

My teaching interests are:

Health economics and economic evaluation
Health economic modelling for decision making

Current projects

I am currently working on the following projects:

Cost-effectiveness of breast cancer screening in older women (in coordination with the University of Bristol and the Hallamshire Hospital)
Natural history of adverse events following radiotherapy (in coordination with the University of Bristol and Christie Hospital)
Single Technology Appraisal for the treatment of patients with ovarian cancer

Publications

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S (2008). Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Current Medical Research and Opinion 24(5):1473-83.
Dhont P, Trichard M, Largeron N, Rafia R, Bénard S. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium. J Med Econ 2008;11(3):431-448
Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A, Pandor A. Are intensive lipid lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective on the literature. Expert Review of Pharmacoeconomics & Outcomes Research 2009
Purshouse RC, Meier PS, Brennan A, Taylor KB, Rafia R (2010). Alcohol pricing policies: Estimated impact on health outcomes and health economic outcomes in England. The Lancet 375(9723):1355-64.
Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro P, Mancardi G, Kozak T, Farge D, Madan J, Rafia R, Akehurst R, Snowden JA on behalf of the EBMT Working Party in Autoimmune Diseases (2010). Autologous haematopoietic stem cell transplantation for the treatment of secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant 45(6):1014-21. Epub 2009 Oct 26.
Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M. Prescribing high dose lipid-lowering therapy early to avoid subsequent cardiovascular events - Is this a cost-effective strategy? (accepted in the European Journal of Cardiovascular Prevention)